CRPC

Real-world Analysis of PTEN Status as a Genetic Biomarker for mCRPC
A recent study from Shilpa Gupta, MD, and colleagues, published in JCO Precision Oncology, investigated the potential of PTEN status to serve as a genetic biomarker for patients with metastatic castration-resistant prostate cancer (mCRPC). Researchers noted that around 40% to 50% of patients with mCRPC functionally lose the PTEN tumor suppressor gene and that little information exists on the prognostic capabilities of PTEN status identified with genetic testing. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Latest News